1L Non-small cell lung carcinoma
ORICORIC PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Enozertinib (ORIC-114) + amivantamab SC in 1L Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
Collab w/ JNJ. 8/12/25- Enrollment continues. 11/13/25:- Ph1b SC amivantamab combo enrollment ongoing; data expected Mid-2026. 01/12/26:- 2H 2026 1L EGFR exon 20 combo SC amivantamab data planned. 02/23/26:- Reiterated plan for 1L NSCLC Ph1b SC amivantamab combo data in 2H 2026. 05/04/26:- Ongoing Ph1b 1L NSCLC SC amivantamab combo enrollment; 2H 2026 efficacy and safety data still expected. 08/03/26:- SC amivantamab combo data reiterated for H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.